和铂医药-B(02142)今日盘中大涨14.42%,引起了市场的广泛关注。
消息面上,和铂医药发布公告,根据股东批准的购回股份授权,公司拟于公开市场上购回价值不超过4000万港元的公司股份,这一举措旨在维护公司及股东整体利益,有望提振投资者对公司长期发展前景的信心。
另一个利好消息是,和铂医药合作的科伦博泰公司的1类新药塔戈利单抗注射液上市获批。此前和铂医药已获得该产品在全球(除大中华地区外)市场的独家开发、生产和商业化权利,未来可能带来不菲收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.